App-Quantinova.ai

NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells

Fiona G. McKissock - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

NUC3373

A study using census and population-based case-control study data

Brittny Davis Lynn - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors

Margarida Neves - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

N/A

IMC-F106C, a novel and potent immunotherapy approach to treat PRAME expressing solid and hematologic tumors

Sylvie Moureau - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

A lncRNA-histone acetyltransferase complex induces colorectal oncogenesis through regulation of a metabolic kinase network

Christos Polytarchou - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Identification of Src's role in governing chemotherapy resistance in oesophageal adenocarcinoma through functional genomic and high-throughput drug screening approaches

Niamh Helen McCabe - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

saracatinib

NUC-1031 causes release of DAMPs and upregulates PD-L1 expression in lung cancer cells

Jennifer Br - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Acelarin

A confirmatory study to probe the reproducibility of cancer cell lines as lab tools to identify molecular subtype-specific therapies and therapeutic targets against glioblastoma stem-like cells

Ann-Christin Nickel - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Weight change in adulthood and colorectal adenoma incidence in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Shisi He - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Peri-operative FLOT: West of Scotland regional experience

K. Welsh - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma

R. Xu - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Capecitabine and oxaliplatin

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life

E. Una Cidon - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Gemcitabine

FOLFIRINOX in borderline resectable pancreatic carcinoma

E. Una Cidon - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

FOLFIRINOX

Multimodal treatment in metastatic colorectal cancer improves outcomes: A University College London Hospital experience

N. Joharatnam-Hogan - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

P. Hammel - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

FOLFIRI

phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22

M. Terada - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

FLYWCH1 regulates intestinal stem cells and tumorigenesis by modulating Wnt/β-catenin signaling

S. Almozyan - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress

A. Vogel - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Pembrolizumab

Defining novel regulators of inflammatory signaling in pancreatic cancer

J. Parry - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Supportive medication in advanced biliary tract cancers with ABC-02 regimen

J. Howells - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced biliary tract carcinoma

N/A

Filters

45280 Abstracts